Magseed Approval Extended in Europe for Soft Tissues, Long-Term Implantation

Magseed Approval Extended in Europe for Soft Tissues, Long-Term Implantation
Magseed, a small magnetic marker by Endomag designed to accurately mark the site of cancer cells before surgery, is now approved in Europe for use in any soft tissue and for long-term implantation, the company said. Magseed was previously approved to guide surgeons during breast cancer surgery, and could only be implanted up to 30 days before surgery. The European Medicines Agency approval extends its use to other tissues, including lymph nodes, lung, and thyroid tissue, and removes the restrictions on the length of time the marker can remain in the body. This extension follows a similar decision by the U.S. Food and Drug Administration (FDA) in February 2018, also clearing Magseed for additional tissues and longer implantation time. “Ever since we launched the Magseed marker, we have been asked by European physicians if they can use it to mark a variety of different cancer sites in the body, which also require a longer implantation than the 30 days we had in Europe," Eric Mayes, CEO at Endomag, said in a press release. "We received this expanded indication from the FDA last year, and I’m delighted that Endomag is the first to offer this same level of targeted treatment to European cancer patients.” An increasing number of women with breast cancer are being treated with chemotherapy prior to surgery to help reduce tumor size. However, this makes it hard
Subscribe or to access all post and page content.